Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International.

Slides:

Advertisements

Similar presentations

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation Karen Ballen, Kwang Woo Ahn, Min Chen, Hisham.

Advertisements

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Timothy S.

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma Baldeep Wirk, Timothy S. Fenske,

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J

Gupta V, Tallman MS, Weisdorf DJ

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Biology of Blood and Marrow Transplantation

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is.

Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents Thomas G. Gross, Gregory A. Hale,

Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia Karen K. Ballen, Ann E. Woolfrey, Xiaochun.

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C

Outcome of Transplantation for Myelofibrosis

Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma Marcel P. Devetten,

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia Jennifer.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure César O. Freytes, Mei-Jie Zhang,

Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of.

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival Brian L. McClune, Kwang Woo Ahn, Hai-Lin.

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome Haesook T. Kim, Philippe Armand,

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia

Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International.

Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation Shaji Kumar, Waleska S. Pérez, Mei-Jie.

Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International.

Jeffrey Schriber, Manza-A. Agovi, Vincent Ho, Karen K

Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling.

The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Karim E. Abou-Nassar, Haesook.

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation Ibrahim.

Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Blood and Marrow Transplant Handbook

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission

Patrick J. Stiff, Manza-A. Agovi, Karen H

One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human.

Fig 1. Cumulative incidence of (A) nonrelapse mortality (P =

Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation Philippe Armand, Haesook T. Kim, Joanna Rhodes,

Presentation transcript:

Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study Philippe Armand, Haesook T. Kim, Mei-Jie Zhang, Waleska S. Perez, Paola S. Dal Cin, Thomas R. Klumpp, Edmund K. Waller, Mark R. Litzow, Jane L. Liesveld, Hillard M. Lazarus, Andrew S. Artz, Vikas Gupta, Bipin N. Savani, Philip L. McCarthy, Jean-Yves Cahn, Harry C. Schouten, Jürgen Finke, Edward D. Ball, Mahmoud D. Aljurf, Corey S. Cutler, Jacob M. Rowe, Joseph H. Antin, Luis M. Isola, Paolo Di Bartolomeo, Bruce M. Camitta, Alan M. Miller, Mitchell S. Cairo, Keith Stockerl-Goldstein, Jorge Sierra, M. Lynn Savoie, Joerg Halter, Patrick J. Stiff, Chadi Nabhan, Ann A. Jakubowski, Donald W. Bunjes, Effie W. Petersdorf, Steven M. Devine, Richard T. Maziarz, Martin Bornhauser, Victor A. Lewis, David I. Marks, Christopher N. Bredeson, Robert J. Soiffer, Daniel J. Weisdorf Biology of Blood and Marrow Transplantation Volume 18, Issue 2, Pages 280-288 (February 2012) DOI: 10.1016/j.bbmt.2011.07.024 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Transplantation outcomes for patients classified by the CIBMTR grouping scheme. (A) OS. (B) LFS. (C) CIR. (D) Cumulative incidence of NRM. Biology of Blood and Marrow Transplantation 2012 18, 280-288DOI: (10.1016/j.bbmt.2011.07.024) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 OS of patients classified according to the CIBMTR schema, stratified by disease status. (A) Patients undergoing transplantation in CR1. (B) Patients undergoing transplantation in CR2. Biology of Blood and Marrow Transplantation 2012 18, 280-288DOI: (10.1016/j.bbmt.2011.07.024) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 OS of patients classified according to the CIBMTR schema, stratified by donor type. (A) Patients receiving an MRD transplant. (B) Patients receiving a URD transplant. Biology of Blood and Marrow Transplantation 2012 18, 280-288DOI: (10.1016/j.bbmt.2011.07.024) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 OS of patients classified according to the CIBMTR schema, stratified by conditioning intensity. (A) Patients undergoing transplantation with myeloablative conditioning. (B) Patients undergoing transplantation with RIC. Biology of Blood and Marrow Transplantation 2012 18, 280-288DOI: (10.1016/j.bbmt.2011.07.024) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions